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2Summary1
Somatic hypermutation of immunoglobulin variable region genes occurs within germinal centres2
(GCs) and is the process responsible for affinity maturation of antibodies during an immune3
response. Previous studies have almost exclusively focused on the immune response to haptens,4
which may be unrepresentative of epitopes on protein antigens.  In this study, we have exploited a5
model system that uses transgenic B- and CD4+ T-cells specific for hen egg lysozyme (HEL) and a6
chicken ovalbumin peptide, respectively, to investigate a tightly synchronised immune response to7
protein antigens of widely differing affinities, thus allowing us to track many facets of the8
development of an antibody response at the antigen-specific B-cell level in an integrated system in9
vivo.10
Somatic hypermutation of immunoglobulin variable genes was analysed in clones of11
transgenic B-cells proliferating in individual GCs in response to HEL or the cross-reactive low12
affinity antigen, duck egg lysozyme (DEL).  Molecular modelling of the antibody-antigen interface13
demonstrates that recurring mutations in the antigen-binding site, selected in GCs, enhance14
interactions of the antibody with DEL.  The effects of these mutations on affinity maturation are15
demonstrated by a shift of transgenic serum antibodies towards higher affinity for DEL in DEL-16
cOVA immunized mice.   The results show that B-cells with high affinity antigen receptors can17
revise their specificity by somatic hypermutation and antigen selection in response to a low18
affinity, cross-reactive antigen.  These observations shed further light on the nature of the immune19
response to pathogens and autoimmunity and demonstrate the utility of this novel model for20
studies  of the mechanisms of somatic hypermutation.  21
22
23
3Introduction1
Following antigen challenge, antigen-specific B-cells enhance the “quality”, i.e. specificity2
and affinity, of the antibodies they produce over time. This process is important for protective3
immunity to pathogens and defects in this process lead to a profound susceptibility to bacterial4
infections 1, 2.5
This improvement in antibody affinity and specificity takes place in the microenvironment6
of the germinal centre (GC) by the process of affinity maturation of B-cell antigen receptors 3-5.7
Firstly, rearranged immunoglobulin (Ig) variable (V) region genes are randomly mutated in8
centroblasts within the dark zone of the GC by a process known as somatic hypermutation 6-9.9
Surface expression of these mutated Igs is upregulated during differentiation of the centroblasts to10
centrocytes, which migrate to the light zone. Here they are pre-programmed to die by apoptosis11
unless they receive survival signals by ligation of the B-cell receptor (BCR) with antigen which they12
encounter on the surface of follicular dendritic cells (FDCs). Competition for antigen results in13
selection of B-cells with high affinity receptors. The surviving B-cells receive further signals from14
CD4+ helper T-cells via their CD40 ligand and differentiate into either long-lived memory cells or15
antibody-producing plasma cells 3, 10.16
Basic features of the hypermutation process have been deduced from the sequences of17
antibodies recovered from different stages of immune responses to a variety of antigens and haptens18
11
. Single nucleotide substitutions are introduced in a stepwise manner into the Ig V region genes at19
an estimated rate of one mutation per thousand base pairs per generation 6. Mutations occur in both20
DNA strands 12 with a strong bias for transitions over transversions 8 and the mutation machinery21
targets particular sequence motifs, or “hot spots” of which the RGYW motif is best known 13-15.22
4Somatic hypermutation in GCs has primarily been studied in mice responding to haptens, in1
which the response is dominated by single rearranged heavy and light chain V- genes 16-18. It has2
been difficult to examine the germinal centre response to protein antigens directly in vivo due to the3
low precursor frequency and heterogeneity of B cells specific for a particular protein and the4
presence of multiple epitopes on the antigen, resulting in a response comprising a very5
heterogeneous population of rearranged V- genes 19.  In this study, we have exploited an adoptive6
transfer mouse model 20 which uses antigen receptor transgenic (Tg) B- and CD4+ T-cells specific7
for hen egg lysozyme (HEL) and a chicken ovalbumin (cOVA) peptide, respectively, to investigate8
a tightly synchronised immune response to a protein antigen. Increasing the precursor frequency of9
T and B lymphocytes to defined epitopes in this model has greatly facilitated studies on  B-cell10
differentiation and migration into the lymphoid follicle 20, 21, receptor-editing of anergic B-cells 2211
and self/non-self B-cell discrimination 23, 24.12
The MD4 mouse strain 23 carries rearranged heavy and light chain transgenes which encode13
the HEL–specific monoclonal antibody, HyHEL-10, offering an unique opportunity to study B-cell14
somatic hypermutation in germinal centres during the immune response to a protein antigen in vivo.15
We have exploited the fact that the HyHEL-10 antibody has approximately three thousand times16
lower affinity for duck egg lysozyme [Ka= 1.3 x 107M-1 (25)] compared to HEL (Ka =4. 5 x 1010M-17
1) but the MD4 Tg B-cells are still able to expand in response to this lower affinity antigen 26.18
The availability of the high resolution 3-D structures of HyHEL-10, its antigen and the19
antibody/antigen complex 27-29 has allowed us to use molecular modelling to study the effects of20
mutations in B-cell clones proliferating within developing GCs.  Molecular modelling of the21
HyHEL-10/DEL interface indicates that antigenic selection for mutations that enhance interactions22
with DEL specific residues is taking place within the GCs of DEL-cOVA immunized recipients.23
5Selection of these mutations was accompanied by increased affinity of the transgenic antibodies for1
DEL.2
To our knowledge, this is the first time that selection of replacement mutations in GC B-3
cells responding to a protein antigen has been observed directly in vivo and their effects on the4
affinity of the antibody-antigen interaction followed through high resolution modelling of the5
receptor/antigen complex. This study expands our understanding of the individual and cumulative6
effects of somatic hypermutation on the binding of antibody to its epitope, leading to further7
insight into how the immune system combats infectious diseases by refinement of the antibody-8
antigen interaction during the evolution of the immune response.9
10
Methods and Materials11
12
Preparation of  DEL-cOVA and HEL-cOVA conjugates13
Lysozyme was prepared from domestic duck eggs following the method previously described by14
Smith-Gill et al 30. It was free of contaminants as determined by SDS-PAGE and was shown to15
contain high specific activity by the Micrococcus lysodeikticus cell turbidimetric assay 31.16
Duck egg lysozyme or hen egg lysozyme (Biozyme laboratories) was coupled to chicken17
ovalbumin (Sigma) using glutaraldehyde [Sigma 20].18
19
Mouse strains, adoptive transfer and immunization20
D011.10 (BALB/c x C57BL/6) F1 and MD4 (BALB/c x C57BL/6) F1 transgenic (Tg) mice were21
used. All mice were bred and maintained in a specific pathogen-free facility at the University of22
Glasgow following home office regulations. D011.10 T-cells express a Tg TCR specific for chicken23
ovalbumin peptide (323-329) in the context of 1-Ad 32. Cell suspensions containing 1 - 2.5 x 10624
6D011.10 CD4+ T-cells and 2.5 - 5 x 106 MD4 B-cells were transferred intravenously into (BALB/c-1
Ighb x C57BL/6)F1 recipients 20. After one day, HEL-cOVA or DEL-cOVA conjugate (130µg) in2
complete Freund’s adjuvant (CFA) was injected subcutaneously on the back. The Tg TCR was3
detected by the clonotypic monoclonal antibody KJ1-26 33. MD4 B-cells express the anti-HEL4
HyHEL-10 monoclonal antibody with both IgM and IgD isotypes 23 and can be identified using an5
antibody specific for the IgMa allotype. The percentage of CD4+ KJ1-26+ D011.10 T-cells and6
B220+ IgMa+  MD4 B-cells from the transgenic donors was determined by flow cytometry.7
8
Immunohistochemistry/FACS9
The lymph nodes (brachial, axillary, cervical, inguinal, and para-aortic) were harvested at specific10
time points; half of the lymph nodes from each recipient were used to prepare single cell11
suspensions and stained for flow cytometry as previously indicated 20. FACS data were collected12
and analysed using FACScalibur (Becton Dickson) and the Cellquest software program,13
respectively.14
The remaining lymph nodes were frozen in liquid nitrogen in O.C.T. embedding medium15
(Miles) and stored at -80°C. Tissue sections (6µM) were mounted on pre-coated slides (Speci-16
microsystems, Surrey), fixed in acetone and stained with biotinylated anti-IgMa, HEL, DEL, peanut17
agglutinin (PNA) and anti-Thy1.2 as previously described  20.18
19
Competitive ELISA20
All reagents were diluted in ED buffer (0.2% fetal calf serum, 0.05% Tween 20 in PBS) unless21
stated otherwise. Sera from recipients were diluted and mixed with various quantities of hen egg22
lysozyme (1µg/ml – 5pg/ml) or duck egg lysozyme (0.125mg/ml – 0.1µg/ml) and incubated at 4°C23
7overnight. The titre of free anti-IgMa serum antibodies in solution was assayed by ELISA on plates1
(Immulon-4) coated with either 20µg/ml DEL or HEL diluted in PBS. Detection was achieved using2
biotinylated anti-mouse IgMa (PharMingen) followed by extravidin peroxidase conjugate (Sigma).3
4
Microdissection, PCR amplification and cloning of the HyHEL-10 light and heavy chain V5
transgenes6
Germinal centres stained with the anti-allotype antibody IgMa and PNA (Vector) were excised by7
microdissection under Scott’s tap water substitute (0.35% NaHCO3, 0.2% MgS04) using a Nikon8
Narishige micromanipulator. Photographs were taken with a Nikon Diaphot inverted microscope9
and a CCD camera. The tissue was digested in 30µl of proteinase K (1.43mg/ml; Boehringer10
Mannhiem) for 1 hour at 50°C followed by heat-inactivation at 95°C for 10 minutes.11
The HyHEL-10 heavy and light V(D)J transgenes were amplified by two rounds of12
polymerase chain reaction (PCR) using Expand DNA polymerase (Boehringer Mannheim) and13
nested oligonucleotide primers (Table I). To avoid contamination of reagents with amplified Ig V14
genes, all procedures before PCR took place in a separate laboratory from that where PCR15
amplification and all subsequent DNA manipulations were performed.16
HyHEL-10 Vκ and VH genes contain 2 and 13 nucleotide differences from the closest17
germline genes, Vκ23-43 and VH36-60, respectively 34. The anti-lysozyme HyHEL-10 Ig heavy18
(H) chain gene construct consists of the LVDJH gene segment, µ-switch and constant regions, µ-19
membrane exons, the δ-constant, secretory and membrane gene segments. The anti-lysozyme20
HyHEL-10 Ig light (L) chain gene construct comprises the LVJκ gene segment and the κ-constant21
region. Both transgene constructs have been described in detail previously 23. External 5’22
oligonucleotides (LL/LH) hybridised to relatively conserved motifs within the immunoglobulin23
8signal sequences of the VH3 or Vκ23 gene families 35. The external 3’ oligonucleotides (IH/IL) were1
specific for the intronic sequences immediately downstream from the JH3 36 or Jκ2 37 gene2
segments. Internal oligonucleotides (VL/JL, VH/JH) were complementary to the 5’ or 3’ ends of the3
rearranged HyHEL10 light and heavy chain V regions, respectively 34, 38.4
The HyHEL-10 light chain V-gene was amplified using the external oligonucleotides LL and5
IL followed by internal primers VL and JL. The HyHEL-10 heavy chain V- gene segment was6
amplified with external oligonucleotides LH and IH followed by internal primers VH and JH.7
The cycling parameters for the PCRs were: 95°C - 2min; (94°C- 1min, 55°C-1min, 72°C-8
2min) x 40; 72°C-15min except the annealing temperature was 52°C for the primary amplification9
of the HyHEL-10 light chain V- gene. A wax-gem (Perkin-Elmer) facilitated hot start was used in all10
PCRs.11
Ten microlitres of the digested tissue was used in all primary amplification PCRs and 2µl of12
the primary PCR product was used in the second amplification step. Negative control samples13
containing water instead of DNA were always amplified in parallel with the DNA from the digested14
tissue. PCR products were purified using either a Qiaquick gel extraction kit or a PCR purification15
kit (Qiagen), ligated into plasmid vector pCR2 and cloned using the TA cloning system (Invitrogen).16
17
Table I approximate position.18
19
Sequencing and analysis of the HyHEL-10 light and heavy chain V region transgenes20
Plasmid DNA was isolated from single clones and positive transformants were chosen at random21
for automated DNA sequencing (DNASHEF, Edinburgh). Sequence chromatographs were analysed22
with Editview and alignments were carried out by DNAplot. The MD4 B-cells contain four copies23
9of the transgene, one copy contains a silent mutation at amino acid position 45 of the Vκ region 391
and was eliminated from any mutational analysis. Dendrograms were produced using sequences2
with shared subsets of somatic mutations cloned from individual germinal centres; each unique3
sequence represents the B cell expressing that mutated V-gene.4
5
Results6
Kinetics of the DEL-cOVA response7
To ensure that DEL coupled to cOVA can elicit B cell help from TCR Tg T cells, as previously8
reported for HEL, we examined the clonal expansion of Tg T and B cells.  HEL-specific Tg B cells9
and OVA-specific TCR T cells were transferred into naïve congenic (BALB/c-Ighb x C57BL/6) F110
mice, which were then immunized with either HEL-cOVA or DEL-cOVA in CFA. The lymph11
nodes were removed from the recipients at days 3, 5, 7, 9 and 14 after immunization, and cells from12
half the lymph nodes were analysed by flow cytometry. The remaining lymph nodes were used for13
immunohistochemical analysis. Clonal expansion of both the Tg D011.10 T and MD4 B cells in14
response to the lower affinity conjugate, DEL-cOVA was detected in vivo. As shown in our15
previous studies 20, 21, the peaks of clonal expansion in response to the high affinity HEL-cOVA16
conjugate were observed on day 3 and 5 for the Tg T and B cells, respectively, (Fig. 1). In contrast,17
following immunization with DEL-cOVA, the expansion of Tg OVA-specific T cells was slower18
than observed in response to the higher affinity, HEL-cOVA. This suggests that B-cells present19
DEL-acquired cOVA less efficiently to T-cells at the earlier stages of GC formation due to their20
lower affinity for DEL-cOVA 40, or alternatively, that the two antigens are presented by21
phenotypically distinct antigen presenting cells.  There was no significant delay in the B-cell22
response to DEL-cOVA compared to HEL-cOVA. This observation is in agreement with a recent23
10
finding that high.and low affinity B-cells have the same intrinic capacity to respond to antigen 41.1
These results demonstrate that the MD4 B cells respond to DEL while receiving help from the2
D011.10 T-cells.3
4
Localisation of Tg MD4 B cells and D011.10 T cells during the DEL-cOVA response5
Following immunisation, antigen–specific T cells undergo clonal expansion and migrate into B-cell6
follicles, where they provide help to B cells 20, 21. Similar follicular migration for both the Tg B and7
T cells was displayed in both the DEL-cOVA and HEL-cOVA immunized recipients.8
PNA–positive GCs containing transgenic IgMa+  B-cells were observed at days 5 to 14 with both9
the high (HEL) and low (DEL) affinity antigens by immunohistochemistry (Fig. 2) and three colour10
flow cytometry (unpublished data). Although numerous anti-HEL-specific Tg B cells were detected11
(Fig. 2a, b) within the GCs of both HEL-cOVA and DEL-cOVA immunized mice, no DEL-binding12
B-cells were detected in the GCs of the DEL-immunized mice (Fig. 2c). The inability to detect13
DEL-binding B-cells may be due to  the sensitivity of the immunochemical system employed. We14
have established a system in which affinity maturation of a trackable population of antigen-specific15
B-cells can be analysed during the germinal centre reaction in vivo.16
17
11
Somatic hypermutation in germinal centres responding to DEL and HEL1
The Vκ and VH region transgenes were amplified by nested PCR from 12 IgMa+ , PNA+ GCs at2
various stages of the primary response to both HEL-cOVA and DEL-cOVA. The GCs were3
identified by PNA staining and consisted of approximately 400-600 cells. Care was taken to avoid4
the inclusion of PNA negative/non-transgenic B-cells in the surrounding area.5
The average mutation rate in the germinal centres for both the HEL-cOVA and DEL-cOVA6
immunized mice was fairly similar ranging from 0.3-0.5% (Table II).7
Table II’s approximate position.8
 There was extensive variability in the mutation rate between germinal centres with the9
occasional GC displaying no mutations within the sample of transgenes analysed. This supports10
previous findings that substantial clonal expansion within germinal centres can occur without11
activation of the hypermutation mechanism 42, 43, although other reports have suggested that12
ongoing mutation may occur in all GCs 44, 45. Inactivation of the hypermutation machinery may be13
advantageous at the early stages of germinal centre formation since the accumulation of  deleterious14
mutations within the GC founder cells would be detrimental.15
Intrinsic mutational hotspots encoded by an RGYW motif [R=A or G, Y = C or T, W = A16
or T] 8, 14 were observed within the VH and Vκ region transgenes of GCs from HEL-cOVA and17
DEL-cOVA immunized recipients (Fig. 3). Mutations at these hotspots tend to produce18
conservative coding changes such as serine to asparagine/threonine, hence preserving antibody19
structure. Additionally, the somatic hypermutation machinery displays a strong bias of transitions20
over transversions  [59% compared with the 33% anticipated on a random bias 8]; 60% of the21
mutations were transitions in this experimental system. These results indicate that somatic22
12
hypermutation of the antigen-specific B-cells was occuring in a primary immune response to a1
protein antigen in vivo.2
3
Clonal proliferation within GCs4
Reconstruction of the hypermutation and clonal expansion events that took place in each GC was5
undertaken using a previously established procedure for building genealogical dendrograms [Fig. 4 42,6
44].7
Potentially affinity-enhancing mutations were retained through a number of cell divisions in8
some B-cell clones (Fig. 4a,b). This may reflect a situation where B-cells with antigen-enhancing9
mutations are being selected and recirculating for additional rounds of somatic mutation (branching10
dendrograms). Many GCs at days 9 and 14 from the HEL-cOVA and DEL-cOVA immunised11
recipients displayed mutationally distinct B-cells emanating from the unmutated transgenes.  These12
dendrograms are described as simple (Fig. 4c) where a number of B-cells containing one or two13
mutations but no shared mutations were observed. These simple dendrograms suggest that there is14
an ongoing emigration of B-cells leaving the GC without further rounds of division and mutation.15
The fact that the transgenic B-cells already have moderate affinity for DEL and high affinity for16
HEL may explain this observation.17
Neighbouring GCs from the same section of lymph node were also examined in two cases18
and no sequences with shared mutations were observed (unpublished data). This is in agreement19
with previous work suggesting that little or no inter GC B-cell migration takes place and that20
somatic hypermutation occurs completely independently in individual GCs 45, 46.21
22
23
24
13
Affinity maturation towards DEL1
Changes in the relative affinity of the HyHEL-10 antibody for DEL and HEL were measured by2
competitive inhibition. Sera from adoptively transferred recipients immunised with either HEL-3
cOVA or DEL-cOVA were analysed at days 9 and 14. HyHEL-10 antibodies in the sera of DEL-4
immunized mice consistently showed increased affinity for DEL, both in solution (Fig. 5a) and in5
solid phase (Fig. 5b), compared with sera from HEL-immunized mice. A unique population of6
DEL-specific Tg antibodies which could not be inhibited at high concentrations of HEL, was7
detected in the sera of DEL-cOVA immunised mice (Fig. 5b). These results provide evidence that8
somatic hypermutation within the Vκ and VH region transgenes resulted in increasing affinity for9
DEL in response to immunisation with DEL-cOVA.10
11
Protein modelling of the affinity maturation process12
a) Differences between HEL and DEL13
High resolution structural characterisation of the HyHEL-10/HEL interaction 27-29 has14
allowed the examination of individual replacement mutations that have occurred within this15
experimental system. Crystallography studies have identified 14 hydrogen bonds, 111 Van der16
Waals contacts and one salt bridge within the interface of the HyHEL-10/HEL complex 28. The17
shape of the antigen-binding site is a very shallow concavity consisting of acidic and non-18
hydrophobic residues, bordered by hydrophobic segments 27. There are 21 differences between the19
amino acid sequence of HEL and DEL [at positions 3, 4, 15, 33, 34, 37, 57, 68, 73, 75, 77, 82, 85,20
90, 91, 92, 93, 97,116, 121, 122; 22 in Duck form III 25] and these amino acids changes were21
modelled using the SwissPdb viewer version 3.3b3.22
23
14
b) Differences between HEL and DEL at the HyHEL-10 antigen binding site1
Of the 21 differences between HEL and DEL, 6 (in bold, above) lie at the antigen-antibody2
interface, by inference from the HyHEL-10/HEL structure.  All 6 occur in one half of the antibody3
interface: CDR2(L), CDR1(H) plus CDR3(H) and not CDR2(H), CDR1(L) or CDR3(L).  This is4
illustrated in Figure 6g.5
This leads to an enquiry as to whether any of these 6 residues are near to any of the6
antibody residues that mutate during the affinity maturation process in vivo.  The answer is one of7
them, viz. residue 93. In HEL, residue 93 is an asparagine whose side chain is specifically hydrogen-8
bonded to the side chain of the 53Vκ glutamine, as seen in Figure 6a.   In DEL, residue 93 is an9
arginine, with a side chain of different hydrogen bond specificity.    10
Nearby, a striking feature of the antigen-binding site in the HyHEL-10/HEL complex is the11
49Vκ lysine, which is prominently exposed and accessible at the centre 27. This residue was seen to12
mutate independently in GC B-cells to an asparagine or a methionine at days 9 and 14, respectively13
(Fig. 5a). The functional importance of these somatic mutations at residue 49Vκ was indicated by14
modelling of the HyHEL-10/DEL interface (Fig. 6b, 6c). The asparagine produced by point15
mutation at residue 49Vκ interacts directly, via hydrogen-bonding, with the DEL-specific amino16
acid, arginine 93 mentioned above. The methionine at 49Vκ may also result in enhanced binding to17
DEL through donation of electrons by the sulphur of the methionine to the guanidino group of18
arginine 93 (Fig. 6c). The importance of this position for antigen binding has been demonstrated by19
site–directed mutagenesis studies in which conversion of the lysine at residue 49Vκ to a threonine20
increased the affinity of the HyHEL-10 antibody for duck egg lysozyme approximately five-fold 25.21
It is remarkable that the predicted importance of mutations at this position has been confirmed in an22
antigen-specific B-cell response in vivo.23
15
c) Other light chain mutations1
At the rest of the antibody-antigen interface where residue changes between HEL and DEL2
are not seen, some κ chain mutations were found in GC B cells.  The serine to asparagine3
replacement mutation at position 93Vκ in CDR3 (Fig. 3a), also previously examined by site-4
directed mutagenesis, does not significantly alter affinity for DEL, at least in the presence of5
threonine at residue 49Vκ 25. Protein modelling of this mutation, which is next to a contact residue,6
displays no alteration in hydrogen bonding within the Ag/Ab interface. Thr/Asn/Asp/Ser amino7
acids often occur in similar hydrogen bonding arrangements and, in such situations, can be8
considered interconvertible 47, 48.9
Serine 91Vκ of the light chain, which is a contact residue in CDR3 with the HEL and DEL10
amino acid tyrosine 20, is believed to be a mutational hotspot.  Conserved coding changes from11
serine 91Vκ to asparagine or threonine were observed at days 5, 9 and 14 in DEL-cOVA responding12
GCs only (Fig. 3a) and modelling suggests the possibility of maintenance of interactions with13
Tyr20.  The Vκ transgenes from DEL-cOVA immunized mice showed a very high preference for14
transition replacements, particularly in CDR3, which may reflect the requirement for modification15
to increase interactions with the lower affinity antigen, DEL.  This is surprising since most of the16
non-identical DEL residues at the Ag-Ab interface are interacting with CDR2(L) and HEL/DEL17
residues close to CDR3(L) are identical.18
Mutations in the framework regions, notably at serine residues 74Vκ and 77Vκ in the light19
chain of monoclonal antibody, HyHEL-8, were also observed in this experimental system.  These20
are considered to be intrinsic hotspots within the light chain nucleotide sequence with conservative21
coding changes that preserve the antibody structure and are unlikely to affect antigen/antibody22
interactions.23
16
d) Heavy chain mutations1
Overall, the variable heavy chain transgene displayed a lower level of mutation compared2
with the light chain, with no mutations shared between independent GCs from the HEL-cOVA and3
DEL-cOVA GCs (Fig. 3b). Protein modelling of the mutation of the CDR2 contact residue serine4
56VH to asparagine, which was observed at day 9 in a DEL-cOVA GC, showed an enhanced5
hydrogen-bond interaction with the lysozyme amino acid, aspartic acid 101, which is present in6
both the HEL and DEL. This mutation also occurs within the HyHEL-8 antibody, which displays7
higher affinity for DEL 25.8
Protein modelling of the other coding changes within and around the CDRs typically9
displayed conserved mutations, which are unlikely to have a major impact on antigen/antibody10
interaction. Since no recurring mutations were observed we cannot rule out the possibility that some11
of these individual mutations may have resulted from PCR error.12
Significantly, no coding changes were detected at the heavy chain residue, aspartic acid13
32VH that is essential for maintaining the salt bridge to lysine/arginine 97 at the HEL and DEL14
interface, respectively. Additionally, little mutation was observed in the lower portion of the15
antigen binding site that is dominated by a cluster of tyrosine residues over the L3 and H2 areas.16
These Tyr amino acids are believed to create more favourable Ag-Ab interactions through their17
clustering effectively preventing contact of any other surrounding residues from direct interaction18
with HEL 27, 49.19
Comparison of patterns of somatic mutation between HEL and DEL-cOVA immunized mice20
Comparison of the total sequence data from GCs of mice immunised with DEL-cOVA and HEL-21
cOVA revealed different patterns of replacement mutations. Coding changes such as the mutations22
at 49Vκ, which increase binding to DEL, were not detected in GCs responding to HEL. Since most23
17
of the unshared DEL residues were in the vicinity of CDR2(L), CDR3(H) and CDR1(H), one might1
predict a larger number of affinity enhancing mutations in that half of the antibody interface. This2
was not observed possibly because any bias would be small due to sample size.3
Three light chain mutations were repeated in distinct GCs responding to HEL and DEL. It is4
unlikely that these mutations could have occurred at random and therefore are likely to have been5
selected during the GC response. Protein modelling indicated that two of the residues at these sites,6
IIe29 and Gln90, are essential for the conservation of the structure of the canonical loops 50, 51.7
According to the canonical class alignment definitions, residue 29 is allowed to be a Val or a Ile, to8
maintain the class 2 L1 loop and the amino acid at position 90 must be either a Gln, Asn or a His9
amino acid to preserve the class 1 L3 loop structure 52. Modelling of the mutations (IIeVκ29→Phe10
and GlnVκ90→Arg) indicated that they were energetically unfavourable, and were likely to make a11
structural change in the loop. These canonically important residues were observed to mutate12
simultaneously with other local amino acids in the same CDR (IleVκ29→Phe with AsnVκ32→Ser,13
GlnVκ90→Arg with SerVκ93→Ile), suggesting that, the local mutations observed in CDRL1 and14
CDRL3 could be compensating for the rearrangement of the CDR loop caused by the mutation of15
these canonical important residues.16
17
Endogenous germline genes18
Since the primers were specific for the Vκ23 and VH36-60 gene families a few rearranged19
germline Vκ and VH genes were also cloned from some of the IgMa+ , PNA+ GCs.  More20
endogenous Vκ23 and VH36-60 genes were cloned from the GCs of DEL-cOVA recipients (35%)21
than from HEL-cOVA immunised animals (3%), which probably reflects competition between the22
transgenic and endogenous B-cells for the lower affinity antigen, DEL. The number of mutations in23
18
these endogenous V genes was similar to the number of mutations observed in the transgenic light1
chains. An endogenous VH-gene (with different D and J regions), that was a constituent of a2
polyreactive anti-histone IgM antibody (Genebank accession no: X63801), was independently3
cloned at day 9 and 14 from DEL-cOVA immunized mice. This VH region is not a documented4
germline gene 11 and has been previously shown to bind HEL 53.5
6
Discussion7
In this study, we have demonstrated affinity maturation of germinal centre B-cells responding to8
two defined protein antigens at the cellular and molecular level directly in vivo using a novel9
adoptive transfer model. This in vivo system exploits the different affinities of the HyHEL-1010
antigen receptor for the monomeric protein antigens, hen egg lysozyme (Ka = 4.5 x 1010M-1) and11
duck egg lysozyme (Ka = 1.3 x 107M-1) and the fact that their conjugation to chicken ovalbumin12
allows provision of T-cell help by cOVA specific D011.10 T-cells 20, 21. Previous in vitro and in13
vivo studies have examined various individual components (clonal expansion, GC formation,14
affinity maturation) of the antibody response but to our knowledge no sequential detailed analysis15
of the overall process to a protein antigen has been performed. This system has allowed us to track,16
in detail, at the level of antigen-specific B cells in vivo, all of these molecular and cellular events that17
occur during the development of an antibody response in one integrated experimental system. Not18
only will this have implications for a variety of therapeutic approaches but it also provides an ideal19
system for studying the mechanisms underlying somatic hypermutation in vivo.20
To ensure that DEL coupled to cOVA can elicit B cell help from TCR Tg T cells, as21
previously reported for HEL, we examined the clonal expansion of Tg T and B cells.  Tg T-cells22
responded more slowly to immunisation with DEL-cOVA than with the higher affinity antigen23
(HEL-cOVA).  This slower T- cell response could be due to the low affinity of the BCR for DEL24
19
resulting in less efficient presentation to T-cells and hence slower recruitment of T-cell help 40.1
Alternatively, the lower affinity of the BCR for DEL may lead to competition for antigen between2
B-cells and other antigen-presenting cells such as dendritic cells for presentation to T-cells.3
Comparison of the levels of endogenous anti-cOVA IgG1 and IgG2a produced in response to HEL4
and DEL-cOVA indicates that the latter interpretation may be correct (unpublished data).  Previous5
in vitro work has shown that, as the affinity of the BCR increases, there is a corresponding6
diminution in the amount of soluble antigen required to trigger a response, until the ability to7
discriminate further increases in affinity disappears above 1010M 54-56. Our study demonstrates for8
the first time  that discrimination between a moderate (Ka= 107M-1) and a high affinity (Ka= 5 x9
1010M-1) antigen also occurs during antigen presentation in vivo.10
As we demonstrated that T and B cell clonal expansion occurs with HEL-cOVA and DEL-11
cOVA we were next able to employ the system to examine somatic hypermutation. To date,12
somatic hypermutation has only been investigated in GCs responding to haptens, due to the13
complexity and heterogeneity of the immune response to protein antigens. Many more contacts14
occur at the Ab-protein interface, which covers a much larger area, hence the process of antigenic-15
selection may be very different during the response to a protein antigen compared with the anti-16
hapten response.17
The overall mutation rate within the GCs of this adoptive transfer system was fairly low18
(0.4%) but was significantly higher than the PCR error rate [0.08%;57] and comparable with19
mutation rates from other primary responses 45, 58.  Characteristics associated with somatic20
hypermutation such as a bias towards transitions and intrinsic hotspots, were also observed in the21
B-cell transgenes. These results confirm the findings of other workers 39 who have also shown22
20
somatic hypermutation in the HyHEL-10 Vκ transgene in Peyer’s patches of intact MD4 mice.1
However, in this case the antigen driving the response was unclear.2
Possible reasons why the mutation rate is low in the system we describe are numerous.3
Firstly, the heavy and light chain transgene cassettes are present in multiple copies and co-4
integrated into the genome, but not at the endogenous Igh and Igκ loci, in the MD4 transgenic5
mouse strain 23.  Each Tg cassette contains a strong Ig promoter and the intronic enhancer, which are6
essential elements for the initiation of somatic hypermutation 59-61. This study and previous work7
verify that the correct placement of the transgenes within the Ig locus  is not critical for mutation 39,8
62-64
. However, the Ig heavy chain 3’ enhancer downstream from the Cµ region is not present. Prior9
work has indicated that the lack of a 3’ heavy chain enhancer reduces the rate of somatic10
hypermutation 65, 66, which could explain the lower mutation rate observed in the heavy chain11
transgene compared with the κ transgene in which the 3’ enhancer is present. Additionally, the Vκ12
and VH HyHEL-10 transgenes contain 2 and 13 nucleotide differences from the nearest germline13
genes, Vκ23 and VH36-60, respectively 34. Some of these are in mutational hotspots, which are14
therefore no longer available for targeting. Finally, the HyHEL-10 BCR displays a moderate affinity15
for DEL, hence the low accumulation of mutations could be explained by ongoing emigration of Tg16
B-cells without the requirement for recycling, since they can receive adequate survival signals17
through the BCR. Some GCs contain many B-cells that have acquired one or two unique mutations18
only, indicating that they do not contain numerous recycling B-cells. Additionally, other19
experimental systems may be observing memory B-cells, recycling through germinal centres for20
further rounds of mutation. The transgenic B-cells are unable to develop into memory cells due to21
the absence of switch recombination sites 67.22
21
Having demonstrated somatic hypermutation, we next determined whether the changes1
observed would be predicted to lead to an increase in affinity for the antigens in question.2
Competitive inhibition studies demonstrated an increase in affinity of serum antibodies, produced3
by transgenic B-cells, towards DEL in DEL-cOVA immunized mice. Strong evidence for selection4
of mutations that shift the affinity from HEL to DEL is provided by the systematic detection of the5
light chain framework region mutations, 49Vκ (Lysine → Methionine/Asparagine) in different6
DEL-cOVA recipients. The CDRs of HyHEL-10 are very short and 49Vκ is adjacent to the7
CDRL2, such that lysine 49 is in the centre of the DEL/HyHEL-10 interface. Protein modelling and8
previous site-directed mutagenesis experiments demonstrate that these mutations enhance affinity9
for DEL. Light chain mutations, Lys49Vκ→Thr and Ser93Vκ→Asn, were targeted by site–directed10
mutagenesis 25 due to the observation that  HyHEL-10 and HyHEL-8 monoclonal antibodies, which11
share the same heavy and light chain V-genes (Vκ23, VH36-60), differed in their ability to bind12
lysozymes from several species of birds, due to the positions of their somatically mutated amino13
acid residues 68. Four of the five somatically mutated amino acid residues which differ between the14
HH8 and HH10 light chains [Vκ residues 49, 74, 77, 93; 34] were present within DEL-cOVA GC B-15
cells and these have been shown to increase affinity for DEL seven fold by chain recombination16
experiments 25.  The intrinsic Vκ mutational hotspots Ser74 and 77 may have a subtle effect on17
affinity although they are distant from the antigen-binding site. Although protein modelling can18
suggest local changes in antibody structure, it is unable to predict co-operative alterations in19
structure between somatically mutated residues or long range effects 69, 70. Protein modelling of20
numerous other replacement mutations in the light chain did not reveal direct interactions with DEL.21
Most coding changes appeared to be neutral, conserving antibody-antigen interactions and antibody22
22
structure. Mutations that are neutral in terms of affinity may offer selective advantages towards1
secretion, folding and physical stability 71.2
The observation that the canonically important light chain residues, IIe29 and Gln90 50, 51,3
were independently mutated to  Phe and Arg, respectively, in the HEL-cOVA and DEL-cOVA4
suggests the influence of  selective pressure, although we do not have direct evidence for an effect5
on antigen binding.6
Replacement mutations in GC B-cells responding to HEL-cOVA did not appear to be7
selected since none were repeated independently. The affinity of HyHEL-10 for HEL (4.5 x 1010M-8
1) is believed to be near the effective ceiling for antibodies since B-cells expressing very high affinity9
receptors do not show a significant advantage over this threshold as measured by competition for10
antigen bound to FDCs 72 or improved antigen presentation to T-cells 54. Roost et al. 7311
demonstrated that germline genes encoding antibodies with high affinity for vesicular stomatitis12
virus showed no affinity maturation over the course of the immune response.  Recently, it has been13
shown that antibody fragments with femtomolar affinities can be evolved by mutagenesis in vitro,14
demonstrating that limitations imposed by the antibody architecture are not intrinsically15
responsible for the affinity ceiling 74. Importantly, our data show that B-cells expressing antigen-16
receptors close to their affinity threshold are capable of revising their specificity by somatic17
hypermutation and selection in response to a low-affinity, cross-reactive antigen. This capability18
would allow further repertoire development of high affinity memory B-cells, which could be19
important during the immune response to a pathogen undergoing antigenic drift. However, this20
advantage is offset by the danger that a similar repertoire shift could result in switching from an21
anti-pathogen response towards a low–affinity, cross-reactive autoantigen (antigen mimicry).22
Remarkably, mutations in this in vivo system recur independently at identical residues indicating23
23
that the affinity maturation process within the immune response is extremely selective.  The effects1
of individual point mutations on the affinity of the transgenic HyHEL-10 antibody towards HEL2
and DEL are currently being investigated using scFv antibody fragments and surface plasmon3
resonance.4
To our knowledge, this is the first time that affinity maturation of the GC response to high and low5
affinity cross-reactive protein antigens has been completely followed  through from the clonal6
expansion of B and T cells in germinal centres to the effects of somatic mutations on the interaction7
of the antigen-binding site with its epitope. This model also provides an ideal system for studying8
the mechanisms underlying somatic hypermutation in vivo.9
10
11
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Figure Legends20
Figure 1.  Kinetics of D011.10 T- and MD4 B-cell clonal expansion after immunisation.21
Cell suspensions containing 1-5 x 106 CD4+KJ1.26+ T cells and B220+ HEL+ B cells were22
transferred into BALB/c-Ighb x C57BL/6 F1 mice. On day 0, transferred recipients were injected s.c.23
with either 130µg of HEL-cOVA or DEL-cOVA in CFA. The percentage of A) D011.1024
24
(CD4+KJ1.26+) T cells and B) MD4 (B220+IgMa+) B-cells in the lymph nodes of adoptively1
transferred recipients were determined by flow cytometry at days 3, 5, 7, 9 and 14 after2
immunisation. Each time point represents the mean ± range for at least two mice per group.3
Unimmunized controls from each time point were averaged and represented as day 0.4
5
Figure 2.  Immunohistochemical analysis of GCs in lymph nodes of HEL-cOVA and DEL-cOVA6
immunised mice.7
The consecutive sections were stained with either anti-Thy1.2 (brown) or peanut agglutinin (PNA)8
and either anti-IgMa , HEL or DEL (blue). Magnification was at x100.9
A) Germinal centre from a HEL-cOVA immunised mouse, d9, IgMa+  Thy1.2+ (left) and10
HEL+PNA+ (right).11
B) Germinal centre from a DEL-cOVA immunised mouse, d9, IgMa+Thy1.2+ (left) and HEL+PNA+12
(right).13
C) Germinal centre from a DEL-cOVA immunised mouse, d9, DEL- PNA+14
15
Figure 3.  Representative examples of the Vκ and VH sequence data obtained from GCs at various16
stages of the HEL-cOVA/DEL-cOVA response.17
Each sequence is compared to the relevant HyHEL-10 transgene,: (A)  Vκ; (B) VH.  Sequences of18
CDR1/CDR2 and CDR3 are completely shown as well as the flanking sections where somatic19
mutation was observed. Identity with the transgene is indicated by a dash and nucleotide differences20
are shown. The number of days after immunization and the antigen used are indicated in the left21
hand column. Numbers in front of the sequence alignment are arbitrary sequence names and the22
25
letter depicts the different isolated germinal centres.  The CDRs in this figure are labeled according1
to Lavoie et al.,1999 34 and the amino acids in bold represent contact residues.2
3
Figure 4.  Clonal proliferation of B-cells within individual GCs4
A simplified hypothesis that each V-gene containing a unique set of mutations represents a distinct5
GC B-cell was made. Each branch of the dendrogram represents mutations that were shared by6
several V-genes, using the assumption that the mutation event only occurred once in a precursor cell7
and was inherited by daughter cells. Numbers on branches represent the number of mutations (silent8
mutations are enclosed in brackets) between the different sequences. Each circle symbolises a  B cell9
and letters within the circles depict individual sequences.10
Branching dendrograms represent VH (A) and Vκ (B) sequences derived from independent GCs11
from day 9 and 14, respectively, in the DEL-cOVA response. The VH antigen-selected hotspot12
Ser56→Asn is symbolised by B-cells, I, J and K on the right hand side of the dendrogram A. The13
‘affinity enhancing’ mutation Lys49→Met of VL is depicted by letters E, F, G and H on the left14
hand side of the dendrogram B, and B-cell, H, also contains the intrinsic hotspots, Ser77→Ile and15
Ser91→Asn. (C) depicts a simple dendrogram produced from the Vκ sequence data from a HEL-16
cOVA GC.17
18
Figure 5.  Relative affinity of IgMa transgenic antibodies in sera from HEL-cOVA and DEL-cOVA19
immunised recipients at days 9 and 14, by competitive ELISA. A) Competitive binding of IgMa20
antibodies to HEL (solid phase) by DEL (soluble phase); B) Competitive inhibition of IgMa21
antibodies to DEL (solid phase) by HEL (soluble phase); (average of two identical experiments).22
23
26
1
Figure 6.  Protein modelling of antibody – lysozyme interactions.2
 A) An area of the antigen-binding site showing details of the interactions between HEL and the3
mouse HyHEL-10 anti-HEL antibody, based on the crystal structure of the Fab-antigen complex4
(28).  B) Model of the same region showing the effects of the LysVκ49 ’ Asn mutation on the5
interaction between the maturation mutant antibody and DEL.  C) Model of the same region6
showing the effects of the LysVκ49’ Met mutation on the interaction with DEL.   D-G are views7
of the HyHEL-10 antigen binding site seen perpendicularly to the antibody-antigen interface.   D)8
employs the colour scheme of F and shows the position of the interacting side chains of residues9
LysVκ49 (red) and the HEL Asn93 (superimposed in black).   E) shows the two V domains: VH in10
green and Vk in blue.    F) is the same as E with the positions of the CDR regions shown by11
different colours.  Vκ: CDR1, pale blue; CDR2, grass green; CDR3, violet.  VH: CDR1, white;12
CDR2, orange; CDR3, yellow.   G) is the same as F except that the side chains of the six interface13
residues differing between HEL and DEL are superimposed in black.  Their size is reduced in D and14
G for clarity and the residue number is indicated at the right hand side.15
16
27
Table I.  Oligonucleotide primers1
2
Oligo. name Sequence  (5’-3’)
LL TGGAYTYCAGCCTCCAGA
IL TAACACCTGATCTGAGAATG
VL GATATTGTGCTAACTCAGTCTCC
JL TTATTTCCAGCTTGGTCCC
LH TGTTGACAGYCVTTCCKGGT
IH GTTGAATCTTGATTCCCGTT
VH GTGCAGCTTCAGGAGTCAGGA
JH TGCAGAGACAGTGACCAGAGT
3
4
28
Table II.  Summary of sequencing results obtained from individual GCs at different days after1
immunisation with DEL-cOVA or HEL-cOVA.2
3
A. DEL-cOVA –immunised mice4
5
GC Day V gene Description
of B-cell
clones
No. of
unique sequences
No. of
mutations
%
unmutated
transgenes
B 5 H Simple 5 6 63.6 (7/11)a
D 5 L Branching 5 7 55.5 (5/9)
H Simple 3 2 81.8 (9/11)
A 9 L Simple 4 5 42.9 (3/7)
H 9 L Branching 4 7 20 (1/5)
H Extensive
Branching
9 13 33.3 (3/9)
J 9 H Simple 4 5 0 (0/7)
L 9 H No S.Mb 1 0 100 (6/6)
A 14 L Extensive
Branching
7 14 38.5 (5/13)
H No S.M 1 0 100 (11/11)
6
Average VL mutation rate = 0.49%7
Average VH mutation  rate = 0.32%8
9
10
11
12
13
14
15
16
29
1
      B. HEL-cOVA immunised mice2
3
GC Day V chain Description
of B cell
clones
No. of unique
sequences
No. of Mutations %unmutated
transgene
C 9 L Branching 11 15 41.2 (7/17)a
H Branching 9 18 43.8 (7/16)
F 9 L Simple 4 6 30 (3/10)
G 9 L Simple 7 6  40 (4/10)
D 14 H Simple 4 4 70 (7/10)
K 14 L Simple 4 3 40  (4/10)
4
Average VL rate = 0.36%5
Average VH rate = 0.5%6
Results obtained from the analysis of primary GCs over days 5, 9, and 14. Data from individual GCs are shown on7
separate lines. The number of unique somatic mutations per GC was evaluated by counting mutations shared by two or8
more VH/VL clones only once. Average mutation frequency per V gene base pair was calculated by dividing total9
number of somatic mutations observed by the total number of base pairs sequenced. Dendrograms containing a number10
of mutationally distinct B-cells  emanating from the unmutated transgene were described as simple. A branching11
dendrogram represents a number of B-cells with shared and unique mutations, which can be followed along one arm of12
the dendrogram.13
a
 The number of unmutated transgenes in the total number of sequences analysed is shown in parentheses. b  No S.M =14
no mutations were observed.15
16
17
18
19
20
21
22
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